By 2023, Italy's sales in Peptic Ulcer and GORD medicine were stabilizing, with data from 2024 indicating a forecasted value of 684.1 million USD. Over the five-year period until 2028, a consistent year-on-year decline is observed: 2025 experiences a 6.41% drop, followed by a 6.63% reduction in 2026, a further 6.87% decrease in 2027, and a concluding 7.17% shrinkage by 2028. The cumulative average growth rate (CAGR) from 2024 to 2028 demonstrates a negative trend at approximately -6.77% per year.
Future trends to watch for in Italy's Peptic Ulcer and GORD medication market include:
- Increased competition from generic drugs.
- Potential impact of healthcare policy changes and reimbursement strategies.
- Innovation and development in alternative therapies which may mitigate demand.
